Bookmark

Add to MyYahoo RSS

Pfizer News

News on Pfizer (Ticker: PFE) continually updated from thousands of sources around the net.

7 hrs ago | Bangor Daily News

AstraZeneca is tougher Pfizer target as possible bid looms

Pfizer isn't giving up on striking an overseas takeover to cut its tax rate and gain a new pipeline of drugs, even as the potential cost of acquiring AstraZeneca rises.

Comment?

Related Topix: Pfizer, Biotech, Medicine, Healthcare Industry, Parsippany, NJ

Sun Aug 31, 2014

AmericanBankingNews.com

Pfizer Given Average Recommendation of "Buy" by Brokerages

Shares of Pfizer have been given an average rating of "Buy" by the eighteen analysts that are covering the company, Analyst Ratings Network reports .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Sat Aug 30, 2014

Freshnews

Secondary Analysis of AMPLIFY-EXT Examining Predictors of...

Secondary Analysis of AMPLIFY-EXT Examining Predictors of Hospitalization Presented at ESC Congress: Eliquis Significantly Reduced the Risk of All-Cause Hospitalization Versus Placebo in Pa PRINCETON, N.J. & NEW YORK -- -- Bristol-Myers Squibb Company and Pfizer Inc. today announced results of a pre-specified secondary analysis of the Eliquis Phase ... (more)

Comment?

Related Topix: Princeton, NJ, Biotech, Bristol Myers Squibb, Medicine, Healthcare Industry, Excaliard Pharmaceuticals, Bloomsbury Publishing, Publishing, Media, Medarex

BioSpace

Protalix Biotherapeutics, Inc. Announces Conference Call To Discuss...

Protalix BioTherapeutics, Inc. , announced today that it will host a conference call on Wednesday, September 3, 2014 at 8:30am ET to discuss the recent approval of ELELYSO for pediatric patients as jointly announced with Pfizer on August 28, 2014.

Comment?

Related Topix: Plains Resources, Energy, Oil & Gas, Biotech, Medicine, Healthcare Industry, Pfizer, Excaliard Pharmaceuticals, Foldrx Pharmaceuticals, Marketing

Fri Aug 29, 2014

Freshnews

Mast Therapeutics Announces Management Change

Mast Therapeutics, Inc. , an emerging biopharmaceutical company, announced today that Santosh Vetticaden, Chief Medical Officer and Senior Vice President, will be leaving the Company, for personal reasons, in mid-September.

Comment?

Related Topix: Pfizer, Excaliard Pharmaceuticals, Biotech, Medicine, Healthcare Industry, Foldrx Pharmaceuticals, Internal Medicine

Sys-Con Media

InnoPharma Announces FDA Approval of Decitabine for Injection, a Generic Version of DACOGENA

InnoPharma developed the generic formulation of decitabine for injection and entered into an agreement with Sandoz, Inc., pursuant to which Sandoz will sell, market and distribute decitabine for injection in Decitabine for injection is indicated for the treatment of patients with myelodysplastic syndromes including previously treated and untreated, ... (more)

Comment?

Related Topix: Food and Drug Administration, Biotech, Healthcare Industry

Seeking Alpha

Is GlaxoSmithKline A Solid Long-Term Investment?

The Chinese issues have caused the stock price to fall and we believe this fall has created a buying opportunity.

Comment?

Related Topix: Biotech, Medicine, GlaxoSmithKline, Healthcare Industry, Pfizer, Excaliard Pharmaceuticals, Foldrx Pharmaceuticals

Fox News

AstraZeneca boosted by start of new cancer drug trial

Hopes for AstraZeneca's promising cancer drug pipeline were boosted on Friday by news the company had moved its immuno-oncology medicine MEDI-4736 into a mid-stage study in colorectal cancer.

Comment?

Related Topix: Oncology, Medicine, Pfizer, Biotech, Healthcare Industry

Pacific Business Times

Amgen seeks approval for new cholesterol drug

Amgen became the first drugmaker to seek U.S. regulatory approval for a new class of cholesterol-lowering treatments after it submitted an application to the Food and Drug Administration on Thursday for evolocumab.

Comment?

Related Topix: Biotech, Medicine, Amgen, Healthcare Industry, Cholesterol, Health, Food and Drug Administration, Lipitor, Atorvastatin (generic)

Customer Interaction Solutions

Market Analysis: Uncertainty And Recent Gains Could Leave Traders Nervous

The major US index futures are pointing to a lower opening on Thursday, with sentiment suggesting that traders are dreading to take positions in equities.

Comment?

Related Topix: Financial Markets, Biotech, Medicine, Healthcare Industry

Thu Aug 28, 2014

Seeking Alpha

Gilead: Let's Make A Deal

The HCV franchise has transformed Gilead in the past two years from a solid mid-tier biopharma company into a pharma giant with a market cap rivaling Merck and Pfizer.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Merck , Startups, Merck & Co., Bain & Company, Vaccine Company

Business Wire

Press release distribution, EDGAR filing, XBRL, regulatory filings

MARTA, de la Ciudad de Atlanta, Selecciona a BRS Labs como Proveedor de Analtica de Video de Inteligencia Artificial para Mejorar la Seguridad Pblica )--Behavioral Recognition Systems, Inc. , creadora de AISight , la solucion analitica basada en inteligencia artificial que se autoensena a reconocer y alertar sobr... )--Fitch Ratings has affirmed ... (more)

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Food and Drug Administration, Pfizer, Excaliard Pharmaceuticals, Foldrx Pharmaceuticals, Plains Resources, Energy, Oil & Gas

Customer Interaction Solutions

Pfizer and Protalix BioTherapeutics Announce FDA Approval of...

Pfizer and Protalix BioTherapeutics Announce FDA Approval of Pediatric Indication for ELELYSO for Injection, for Intravenous Use for the Treatment of Type 1 Gaucher Disease Pfizer Inc. and Protalix BioTherapeutics, Inc. announced today that the U.S. Food and Drug Administration approved ELELYSO for injection for pediatric patients.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Healthcare Law, Law, Pfizer, Excaliard Pharmaceuticals, Foldrx Pharmaceuticals, Food and Drug Administration

In-PharmaTechnologist.com

Is Pfizer now eyeing up Actavis three months after failed AZ bid?

Pfizer is rumoured to be eyeing up Actavis three months after failing to woo AstraZeneca in a $120bn megamerger, but what would such a deal bring to the Pharma Giant? In-Pharmatechnologist investigates.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Wall Street Journal

Pfizer Vaccine Candidate Gets Fast Track

Pfizer Inc. said Thursday that its candidate to vaccinate against a potentially fatal infection that harms patients' bowels has received fast-track designation from the U.S. Food and Drug Administration.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Food and Drug Administration

BayStreet.ca

SeeThruEquity Issues Quarterly Update on Manhattan Scientifics,...

New York, NY / ACCESSWIRE / August 27, 2014 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a quarterly update on Manhattan Scientifics, Inc. for Q2 2014.

Comment?

Related Topix: Marketing, Forest Laboratories, Pfizer, Biotech, Medicine, Forest Labs, Healthcare Industry

American Academy of Family Physicians

ACIP Recommends Routine PCV13 Immunization for Adults 65 and Older

Aug. 13 to discuss and vote on the use of pneumococcal vaccines in older adults.

Comment?

Related Topix: Medicine, Influenza, Health, Biotech, Healthcare Industry, Centers for Disease Control and Prevention, Healthcare Law, Law, Medicare

Wed Aug 27, 2014

Benzinga

Fast Money Picks For August 28

On CNBC's Fast Money , Pete Najarian said that Pfizer is going higher. He thinks that it has a price target of $36.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Seeking Alpha

Growth Prospects Remain Strong For Pfizer

The healthcare sector has been performing well over the last few months - in fact, most of the BioPharma companies have outperformed most of the sectors and the overall market itself.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Life, Food, Nutrition, Healthcare Law, Law, HIV/AIDS, Health

Benzinga

's Top Initiations

Analysts at Deutsche Bank initiated coverage on Pfizer with a Buy rating. The target price for Pfizer is set to $34.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Garmin, Cable & Satellite, Telecom, Webs, Startups, Oracle Corporation

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••